Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(2):938-955. doi:10.7150/thno.37443 This issue Cite

Review

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Niels Dammes1,2,3,4,5, Dan Peer1,2,3,4,5✉

1. Laboratory of Precision NanoMedicine, Tel Aviv University, Tel Aviv 69978, Israel
2. School of Molecular Cell Biology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
3. Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
4. Center for Nanoscience and Nanotechnology, and Tel Aviv University, Tel Aviv 69978, Israel
5. Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel

✉ Corresponding author: Dan Peer, peertau.ac.il

Citation:
Dammes N, Peer D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics 2020; 10(2):938-955. doi:10.7150/thno.37443. https://www.thno.org/v10p0938.htm
Other styles

File import instruction

Abstract

Graphic abstract

Molecular imaging modalities hold great potential as less invasive techniques for diagnosis and management of various diseases. Molecular imaging combines imaging agents with targeting moieties to specifically image diseased sites in the body. Monoclonal antibodies (mAbs) have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity and serum stability. Because of the same properties, mAbs are also exploited in molecular imaging to target imaging agents such as radionuclides to the cell of interest in vivo. Many studies investigated the use of mAb-targeted imaging for a variety of purposes, for instance to monitor disease progression and to predict response to a specific therapeutic agent. Herein, we highlighted the application of mAb-targeted imaging in three different types of pathologies: autoimmune diseases, oncology and cardiovascular diseases. We also described the potential of molecular imaging strategies in theranostics and precision medicine. Due to the nearly infinite repertoire of mAbs, molecular imaging can change the future of modern medicine by revolutionizing diagnostics and response prediction in practically any disease.

Keywords: molecular imaging, monoclonal antibodies, autoimmune diseases, oncology and cardiovascular diseases.

Citation styles

APA
Dammes, N., Peer, D. (2020). Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics, 10(2), 938-955. https://doi.org/10.7150/thno.37443.

ACS
Dammes, N.; Peer, D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics 2020, 10 (2), 938-955. DOI: 10.7150/thno.37443.

NLM
Dammes N, Peer D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics 2020; 10(2):938-955. doi:10.7150/thno.37443. https://www.thno.org/v10p0938.htm

CSE
Dammes N, Peer D. 2020. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics. 10(2):938-955.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use